PETRONI, GIULIA
PETRONI, GIULIA
Medicina Sperimentale e Clinica
A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy
2013 Lucia Filì;Alessandra Vultaggio;Elisa Cardilicchia;Cinzia Manuelli;Andrea Casini;Francesca Nencini;Laura Maggi;Sara Pratesi;Giulia Petroni;Francesca Boscaro;Antonio Guarna;Ernesto G. Occhiato;Sergio Romagnani;Enrico Maggi;Paola Parronchi
A novel nDer p2-conjugated TLR7 down-modulates Th2-associated lung inflammation by using a therapeutical protocol
2013 Pratesi S ; Nencini F; Petroni G;Cardilicchia E; Fili L; Casini A; Guarna A; Romagnani S; Parronchi P; Maggi E; Vultaggio A
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.
2013 Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A.
Assays and strategies for immunogenicity assessment of biological agents.
2014 Nencini F; Pratesi S; Petroni G; Matucci A; Maggi E; Vultaggio A.
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification
2023 Caliman, Enrico; Fancelli, Sara; Petroni, Giulia; Gatta Michelet, Marta Rita; Cosso, Federica; Ottanelli, Carlotta; Mazzoni, Francesca; Voltolini, Luca; Pillozzi, Serena; Antonuzzo, Lorenzo
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation
2018 Marzo, Tiziano; Pratesi, Alessandro; Cirri, Damiano; Pillozzi, Serena; Petroni, Giulia; Guerri, Annalisa; Arcangeli, Annarosa; Messori, Luigi; Gabbiani, Chiara
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions
2016 Vultaggio A.; Petroni G.; Pratesi S.; Nencini F.; Cammelli D.; Milla M.; Prignano F.; Annese V.; Romagnani S.; Maggi E.; Matucci A.
Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K
2020 Petroni, Giulia; Bagni, Giacomo; Iorio, Jessica; Duranti, Claudia; Lottini, Tiziano; Stefanini, Matteo; Kragol, Goran; Becchetti, Andrea; Arcangeli, Annarosa
Data describing the effects of the Macrolide Antibiotic Clarithromycin on preclinical mouse models of Colorectal Cancer
2019 Petroni G.; Stefanini M.; Pillozzi S.; Crociani O.; Becchetti A.; Arcangeli A.
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab
2012 Alessandra Vultaggio;Andrea Matucci;Francesca Nencini;Sara Pratesi;Giulia Petroni;Daniele Cammelli;Renato Alterini;Luigi Rigacci;Sergio Romagnani;Enrico Maggi
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients
2020 Iorio, Jessica; Lastraioli, Elena; Tofani, Lorenzo; Petroni, Giulia; Antonuzzo, Lorenzo; Messerini, Luca; Perrone, Giuseppe; Caputo, Damiano; Francesconi, Maria; Amato, Maria Michelina; Cadei, Moris; Arcangeli, Giuseppina; Villanacci, Vincenzo; Boni, Luca; Coppola, Roberto; Di Costanzo, Francesco; Arcangeli, Annarosa
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy
2016 Muratori, Leonardo; Petroni, Giulia; Antonuzzo, Lorenzo; Boni, Luca; Iorio, Jessica; Lastraioli, Elena; Bartoli, Gianluca; Messerini, Luca; Di Costanzo, Francesco; Arcangeli, Annarosa
Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications
2014 Andrea Matucci; Giulia Petroni; Sara Pratesi; Francesca Nencini; Enrico Maggi; Alessandra Vultaggio
Immunogenicità dei Farmaci Biologici: Analisi dei Meccanismi Fisiopatologici e Sviluppo di Test in vitro per il suo Monitoraggio
2013 Giulia Petroni
Ion Channel Conformations Regulate Integrin-Dependent Signaling
2019 Becchetti A.; Petroni G.; Arcangeli A.
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions.
2014 Vultaggio A; Nencini F; Pratesi S; Petroni G; Maggi E; Matucci A.
New gold carbene complexes as candidate anticancer agents
2016 Pratesi, Alessandro; Cirri, Damiano; Đurović, Mirjana D; Pillozzi, Serena; Petroni, Giulia; Bugarčić, Živadin D; Messori, Luigi
Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow-induced chemoresistance in acute leukemias
2019 Pillozzi S.; Bernini A.; Spiga O.; Lelli B.; Petroni G.; Bracci L.; Niccolai N.; Arcangeli A.
Potassium and Sodium Channels and the Warburg Effect: Biophysical Regulation of Cancer Metabolism
2019 Jessica Iorio, Giulia Petroni, Claudia Duranti, Elena Lastraioli
Short and long-term effect of a novel nDer p2-conjugated TLR7 ligand in the prevention of allergic lung inflammation
2012 Pratesi S; Petroni G; Vultaggio A; Nencini F; Cardilllicchia E ; Fili L; Casini A; Guarna A; Romagnani S ; Parronchi P ; Maggi E
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy | 2013 | Lucia Filì;Alessandra Vultaggio;Elisa Cardilicchia;Cinzia Manuelli;Andrea Casini;Francesca Nencini;Laura Maggi;Sara Pratesi;Giulia Petroni;Francesca Boscaro;Antonio Guarna;Ernesto G. Occhiato;Sergio Romagnani;Enrico Maggi;Paola Parronchi | |
| A novel nDer p2-conjugated TLR7 down-modulates Th2-associated lung inflammation by using a therapeutical protocol | 2013 | Pratesi S ; Nencini F; Petroni G;Cardilicchia E; Fili L; Casini A; Guarna A; Romagnani S; Parronchi P; Maggi E; Vultaggio A | |
| Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. | 2013 | Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A. | |
| Assays and strategies for immunogenicity assessment of biological agents. | 2014 | Nencini F; Pratesi S; Petroni G; Matucci A; Maggi E; Vultaggio A. | |
| Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification | 2023 | Caliman, Enrico; Fancelli, Sara; Petroni, Giulia; Gatta Michelet, Marta Rita; Cosso, Federica; Ottanelli, Carlotta; Mazzoni, Francesca; Voltolini, Luca; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation | 2018 | Marzo, Tiziano; Pratesi, Alessandro; Cirri, Damiano; Pillozzi, Serena; Petroni, Giulia; Guerri, Annalisa; Arcangeli, Annarosa; Messori, Luigi; Gabbiani, Chiara | |
| Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions | 2016 | Vultaggio A.; Petroni G.; Pratesi S.; Nencini F.; Cammelli D.; Milla M.; Prignano F.; Annese V.; Romagnani S.; Maggi E.; Matucci A. | |
| Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K | 2020 | Petroni, Giulia; Bagni, Giacomo; Iorio, Jessica; Duranti, Claudia; Lottini, Tiziano; Stefanini, Matteo; Kragol, Goran; Becchetti, Andrea; Arcangeli, Annarosa | |
| Data describing the effects of the Macrolide Antibiotic Clarithromycin on preclinical mouse models of Colorectal Cancer | 2019 | Petroni G.; Stefanini M.; Pillozzi S.; Crociani O.; Becchetti A.; Arcangeli A. | |
| Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab | 2012 | Alessandra Vultaggio;Andrea Matucci;Francesca Nencini;Sara Pratesi;Giulia Petroni;Daniele Cammelli;Renato Alterini;Luigi Rigacci;Sergio Romagnani;Enrico Maggi | |
| hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients | 2020 | Iorio, Jessica; Lastraioli, Elena; Tofani, Lorenzo; Petroni, Giulia; Antonuzzo, Lorenzo; Messerini, Luca; Perrone, Giuseppe; Caputo, Damiano; Francesconi, Maria; Amato, Maria Michelina; Cadei, Moris; Arcangeli, Giuseppina; Villanacci, Vincenzo; Boni, Luca; Coppola, Roberto; Di Costanzo, Francesco; Arcangeli, Annarosa | |
| HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy | 2016 | Muratori, Leonardo; Petroni, Giulia; Antonuzzo, Lorenzo; Boni, Luca; Iorio, Jessica; Lastraioli, Elena; Bartoli, Gianluca; Messerini, Luca; Di Costanzo, Francesco; Arcangeli, Annarosa | |
| Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications | 2014 | Andrea Matucci; Giulia Petroni; Sara Pratesi; Francesca Nencini; Enrico Maggi; Alessandra Vultaggio | |
| Immunogenicità dei Farmaci Biologici: Analisi dei Meccanismi Fisiopatologici e Sviluppo di Test in vitro per il suo Monitoraggio | 2013 | Giulia Petroni | |
| Ion Channel Conformations Regulate Integrin-Dependent Signaling | 2019 | Becchetti A.; Petroni G.; Arcangeli A. | |
| Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. | 2014 | Vultaggio A; Nencini F; Pratesi S; Petroni G; Maggi E; Matucci A. | |
| New gold carbene complexes as candidate anticancer agents | 2016 | Pratesi, Alessandro; Cirri, Damiano; Đurović, Mirjana D; Pillozzi, Serena; Petroni, Giulia; Bugarčić, Živadin D; Messori, Luigi | |
| Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow-induced chemoresistance in acute leukemias | 2019 | Pillozzi S.; Bernini A.; Spiga O.; Lelli B.; Petroni G.; Bracci L.; Niccolai N.; Arcangeli A. | |
| Potassium and Sodium Channels and the Warburg Effect: Biophysical Regulation of Cancer Metabolism | 2019 | Jessica Iorio, Giulia Petroni, Claudia Duranti, Elena Lastraioli | |
| Short and long-term effect of a novel nDer p2-conjugated TLR7 ligand in the prevention of allergic lung inflammation | 2012 | Pratesi S; Petroni G; Vultaggio A; Nencini F; Cardilllicchia E ; Fili L; Casini A; Guarna A; Romagnani S ; Parronchi P ; Maggi E |